Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Sponsor
Fudan University
Study ID
NCT00633490
Phase
PHASE1
Status
Unknown

Conditions

  • Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • apatinib — DRUG
    apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily

Study Details

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the drug's toxicity and to find a dose level to be used in a phase II study in solid tumor patients.

Key Dates

Start date
Jul 31, 2007
Status verified
Mar 2008
Primary completion
Jun 30, 2008
Completion
Jun 30, 2008

Study Design

Enrollment
18 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

toxicity and tolerable dosage on the basis of NCI-CTCAE 3.0 [ Time Frame: 4 weeks ]

Central Contacts

Related Studies